South Korean health-tech company Kakao Healthcare has entered into a memorandum of agreement (MOA) with Universitas Indonesia Hospital (RSUI) to collaborate on localizing and disseminating its AI-driven blood sugar management solution, PASTA. The collaboration is part of the company’s strategy to prepare the foundation for introducing PASTA to the Indonesian market.
PASTA, launched in February 2024, utilizes AI and continuous glucose monitoring (CGM) to offer real-time blood sugar readings. It analyzes user-inputted data on diet, exercise, and sleep to provide personalized lifestyle recommendations. Certified as a second-class software medical device by South Korea’s Ministry of Food and Drug Safety, PASTA aims to enhance diabetes management through advanced technology.
The partnership with RSUI follows discussions initiated during the Korea-ASEAN Summit and the subsequent Korea-Indonesia-ASEAN AI Workshop in September last year. At the workshop, the Ministry of Science and ICT emphasized digital cooperation and support for AI-driven healthcare solutions in ASEAN countries.
Under the MOA, Kakao Healthcare plans to adapt PASTA for the Indonesian market by incorporating local healthcare insights and enhancing AI algorithms. RSUI will facilitate a pilot test involving healthcare professionals and patients to evaluate the solution’s effectiveness in local settings. On top of that, Continuous Glucose Monitoring devices (CGM), necessary for the pilot program, will be supplied at no cost by the multinational company Dexcom.
(Source: Korea Biomedical Review)
